Statement of Changes in Beneficial Ownership (4)
March 01 2017 - 12:15PM
Edgar (US Regulatory)
|
FORM 4
[
X
]
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue.
See
Instruction 1(b).
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
|
OMB APPROVAL
OMB Number:
3235-0287
Estimated average burden
hours per response...
0.5
|
|
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
|
|
|
1. Name and Address of Reporting Person
*
Hogan Linda C.
|
2. Issuer Name
and
Ticker or Trading Symbol
CoLucid Pharmaceuticals, Inc.
[
CLCD
]
|
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
_____ Director
_____ 10% Owner
__
X
__ Officer (give title below)
_____ Other (specify below)
Head, Bus. Dev. and Strategy
|
|
(Last)
(First)
(Middle)
C/O COLUCID PHARMACEUTICALS, INC., 222 THIRD STREET
|
3. Date of Earliest Transaction
(MM/DD/YYYY)
3/1/2017
|
|
(Street)
CAMBRIDGE, MA 02142
(City)
(State)
(Zip)
|
4. If Amendment, Date Original Filed
(MM/DD/YYYY)
|
6. Individual or Joint/Group Filing
(Check Applicable Line)
_
X
_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
|
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
|
1.Title of Security
(Instr. 3)
|
2. Trans. Date
|
2A. Deemed Execution Date, if any
|
3. Trans. Code
(Instr. 8)
|
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
|
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
|
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)
|
7. Nature of Indirect Beneficial Ownership (Instr. 4)
|
|
Code
|
V
|
Amount
|
(A) or (D)
|
Price
|
Table II - Derivative Securities Beneficially Owned (
e.g.
, puts, calls, warrants, options, convertible securities)
|
1. Title of Derivate Security
(Instr. 3)
|
2. Conversion or Exercise Price of Derivative Security
|
3. Trans. Date
|
3A. Deemed Execution Date, if any
|
4. Trans. Code
(Instr. 8)
|
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
|
6. Date Exercisable and Expiration Date
|
7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)
|
8. Price of Derivative Security
(Instr. 5)
|
9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)
|
10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)
|
11. Nature of Indirect Beneficial Ownership (Instr. 4)
|
|
Code
|
V
|
(A)
|
(D)
|
Date Exercisable
|
Expiration Date
|
Title
|
Amount or Number of Shares
|
|
Stock Option (Right to Buy)
|
$10.00
|
3/1/2017
|
|
D
|
|
|
46966
|
(1)
|
5/5/2025
|
Common Stock
|
46966
|
$36.50
|
0
|
D
|
|
|
Stock Option (Right to Buy)
|
$7.56
|
3/1/2017
|
|
D
|
|
|
5741
|
(2)
|
8/4/2025
|
Common Stock
|
5741
|
$38.94
|
0
|
D
|
|
|
Stock Option (Right to Buy)
|
$6.75
|
3/1/2017
|
|
D
|
|
|
26594
|
(3)
|
3/4/2026
|
Common Stock
|
26594
|
$39.75
|
0
|
D
|
|
|
Explanation of Responses:
|
|
(
1)
|
Pursuant to the terms of the Agreement and Plan of Merger, dated January 17, 2017 (the "Merger Agreement"), by and among CoLucid Pharmaceuticals, Inc. (the "Issuer"), Eli Lilly and Company ("Lilly") and ProCar Acquisition Corporation, a wholly-owned subsidiary of Lilly, these options, which provided that 33% of the shares vested on May 5, 2016 and the remaining shares vesting in a series of 36 successive equal monthly installments upon completion of each additional month of service, were cancelled in exchange for a cash payment of $46.50 less the per share exercise price multiplied by the number of unexercised options, without interest.
|
|
(
2)
|
These options, which provided that one-third of the shares vested on August 4, 2016 and the remaining shares vesting in a series of 36 successive equal monthly installments upon completion of each additional month of service, were cancelled in exchange for a cash payment of $46.50 less the per share exercise price multiplied by the number of unexercised options, without interest.
|
|
(
3)
|
These options, which provided for vesting in a series of 48 successive equal monthly installments with the first monthly installment vesting on the grant date and the future installments vesting on the first day of each calendar month, were cancelled in exchange for a cash payment of $46.50 less the per share exercise price multiplied by the number of unexercised options, without interest.
|
Reporting Owners
|
|
Reporting Owner Name / Address
|
Relationships
|
|
Director
|
10% Owner
|
Officer
|
Other
|
Hogan Linda C.
C/O COLUCID PHARMACEUTICALS, INC.
222 THIRD STREET
CAMBRIDGE, MA 02142
|
|
|
Head, Bus. Dev. and Strategy
|
|
Signatures
|
|
/s/ Christine G. Long, Attorney-in-Fact for Linda C. Hogan (power of attorney previously filed)
|
|
3/1/2017
|
|
**
Signature of Reporting Person
|
Date
|
|
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
|
|
*
|
If the form is filed by more than one reporting person,
see
Instruction 4(b)(v).
|
|
**
|
Intentional misstatements or omissions of facts constitute Federal Criminal Violations.
See
18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
|
|
Note:
|
File three copies of this Form, one of which must be manually signed. If space is insufficient,
see
Instruction 6 for procedure.
|
|
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
|
COLUCID PHARMACEUTICALS, INC. (NASDAQ:CLCD)
Historical Stock Chart
From May 2024 to Jun 2024
COLUCID PHARMACEUTICALS, INC. (NASDAQ:CLCD)
Historical Stock Chart
From Jun 2023 to Jun 2024
